Immunocompromised Have Heterogeneous Antibody Response to RSV Vaccines
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 7, 2025 -- For immunocompromised individuals, antibody response to respiratory syncytial virus (RSV) vaccines is heterogeneous and about 40 percent do not seroconvert, according to a research letter published online Dec. 30 in the Journal of the American Medical Association.
Andrew H. Karaba, M.D., Ph.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues measured antibody response to RSV vaccinations in immunocompromised individuals in a prospective, national cohort study. Persons with self-reported immunocompromising conditions were enrolled. Those reporting plans to receive adjuvanted RSV prefusion F (preF)3-AS01E or nonadjuvanted RSVpreF were asked to provide blood samples prevaccine and at two, four, and 12 weeks after vaccination. The primary outcome was fold rise in antibody titers from baseline to four weeks; seroconversion was defined as a fourfold or greater rise in preF immunoglobulin G (IgG) at four weeks.
Overall, 139 participants reported RSV vaccination during the study period, and of these, 38 submitted paired baseline and four-week postvaccination samples. The researchers found that the median preF IgG increased from 87,292 AU/mL at baseline to 626,280; 439,086; and 464,170 AU/mL at two, four, and 12 weeks postvaccination, respectively. The median four-week preF IgG fold rise was 4.21; 23 of the participants (61 percent) achieved seroconversion.
"In contrast to universal seroconversion and preF IgG fold rises greater than 10 in immunocompetent persons, approximately 40 percent of immunocompromised participants did not seroconvert or achieve a conservative neutralization threshold postvaccination," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.